Ofir Koren - Nano X General Division
| NNOX Stock | USD 6.36 0.20 3.25% |
Executive
Ofir Koren is General Division of Nano X Imaging
| Age | 54 |
| Address | 94 Shlomo Shmeltzer Road, Petah Tikva, Israel, 4970602 |
| Phone | 972 3 373 59202 |
| Web | https://www.nanox.vision |
Nano X Management Efficiency
The company has return on total asset (ROA) of (0.1715) % which means that it has lost $0.1715 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3118) %, meaning that it created substantial loss on money invested by shareholders. Nano X's management efficiency ratios could be used to measure how well Nano X manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to rise to -0.29 in 2024. At this time, Nano X's Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 91.1 M in 2024, whereas Total Assets are likely to drop slightly above 199 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeff Eidel | Pacific Biosciences of | 47 | |
| MPH MD | Medtronic PLC | N/A | |
| Julie Coletti | Align Technology | 56 | |
| Frank Leonard | Novocure | N/A | |
| Mark Jesser | Integra LifeSciences Holdings | N/A | |
| Melissa Brotz | Abbott Laboratories | N/A | |
| Stephen Leonard | Integra LifeSciences Holdings | 62 | |
| Matthew Dolan | DexCom Inc | 43 | |
| Michael Puri | Novocure | 55 | |
| Stacey Stewart | DexCom Inc | N/A | |
| Arnold JD | Edwards Lifesciences Corp | 65 | |
| Sabina Ewing | Abbott Laboratories | 50 | |
| Stuart Hart | Integra LifeSciences Holdings | N/A | |
| Brett JD | Pacific Biosciences of | N/A | |
| Jason Beach | Stryker | N/A | |
| Chris Tyson | Monogram Orthopaedics Common | N/A | |
| Donald Abbey | DexCom Inc | 57 | |
| Gary Sorsher | Edwards Lifesciences Corp | 59 | |
| Ruth Fleming | Integra LifeSciences Holdings | N/A | |
| Susan Krause | Integra LifeSciences Holdings | N/A | |
| Kamran Shamaei | Monogram Orthopaedics Common | 41 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.17 |
Nano X Imaging Leadership Team
Elected by the shareholders, the Nano X's board of directors comprises two types of representatives: Nano X inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nano. The board's role is to monitor Nano X's management team and ensure that shareholders' interests are well served. Nano X's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nano X's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gali Attias, Chief Resources | ||
| Marina Feler, Chief Officer | ||
| Tal Shank, VP Devel | ||
| Ran Poliakine, Founder Chairman | ||
| Tamar Cohen, Executive Officer | ||
| Ran Daniel, Chief Officer | ||
| Ilung Kim, Head Korea | ||
| Lydia Edwards, Pres US | ||
| Guy Yoskovitz, Chief Officer | ||
| Gilad Yron, Chief Officer | ||
| James Dara, GM USA | ||
| Ofir Koren, General Division | ||
| Noga Shabshin, Head Division | ||
| Orit MD, Chief AI | ||
| Orit Wimpfheimer, Chief AI | ||
| Erez Meltzer, CEO Director | ||
| Sharon Saban, VP Division | ||
| Michael Attias, VP Robodiology |
Nano Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nano X a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (5.36) % | ||||
| Current Valuation | 323.3 M | ||||
| Shares Outstanding | 58.52 M | ||||
| Shares Owned By Insiders | 8.99 % | ||||
| Shares Owned By Institutions | 18.66 % | ||||
| Number Of Shares Shorted | 7.25 M | ||||
| Price To Book | 2.27 X | ||||
| Price To Sales | 36.75 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nano Stock Analysis
When running Nano X's price analysis, check to measure Nano X's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nano X is operating at the current time. Most of Nano X's value examination focuses on studying past and present price action to predict the probability of Nano X's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nano X's price. Additionally, you may evaluate how the addition of Nano X to your portfolios can decrease your overall portfolio volatility.